Robert Pangia - Biogen Independent Director

BIIB Stock  USD 216.34  4.32  2.04%   

Director

Mr. Robert W. Pangia is an Independent Director of Biogen Inc. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDECs merger with Biogen, Inc since 1997.
Age 66
Tenure 27 years
Address 225 Binney Street, Cambridge, MA, United States, 02142
Phone617 679 2000
Webhttps://www.biogen.com
Pangia was a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009 he also served as the Chief Executive Officer of Highlands Acquisition Corporationrationration, a special purpose acquisition company. From 1996 to 2003 Mr. Pangia was selfemployed as an investment banker. From 1987 to 1996 he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc. and a member of several of PaineWebber’s executive and operating committees.

Biogen Management Efficiency

The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0824 %, meaning that it created $0.0824 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.08. The current year's Return On Assets is expected to grow to 0.06. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.
The company currently holds 7.34 B in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Biogen Inc has a current ratio of 2.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biogen until it has trouble settling it off, either with new capital or with free cash flow. So, Biogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biogen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biogen to invest in growth at high rates of return. When we think about Biogen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

DIRECTOR Age

Paul ClarkAgilent Technologies
72
Stephen WillsMediwound
58
Sue RatajAgilent Technologies
63
George ScangosAgilent Technologies
72
Tadataka YamadaAgilent Technologies
74
Aharon YaariMediwound
63
Vickie DriverMediwound
N/A
Mala AnandAgilent Technologies
53
Heidi FieldsAgilent Technologies
60
Hans BishopAgilent Technologies
56
Heidi KunzAgilent Technologies
66
Robert HerboldAgilent Technologies
74
Dow WilsonAgilent Technologies
61
Daniel PodolskyAgilent Technologies
67
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people. Biogen Inc (BIIB) is traded on NASDAQ Exchange in USA. It is located in 225 Binney Street, Cambridge, MA, United States, 02142 and employs 7,570 people. Biogen is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Biogen Inc Leadership Team

Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Viehbacher, CEO President
Robin Kramer, Chief Accounting Officer, Vice President
Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology
Alfred Sandrock, Group Senior Vice President Chief Medical Officer
Spyros ArtavanisTsakonas, Senior Vice President Chief Scientific Officer
Alexander Denner, Independent Director
Natacha Gassenbach, Chief Affairs
Douglas Williams, Executive VP of RandD
JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations
Eric Rowinsky, Independent Director
William Hawkins, Director
Charles Triano, Senior Relations
Kenneth Pietro, Executive Vice President - Human Resources
John Chiminski, Director
Adam Koppel, Senior Vice President and Chief Strategy Officer
Caroline Dorsa, Independent Director
Michael Ehlers, Executive Vice President of Research and Development
Ginger Gregory, Chief Human Resource Officer, Executive Vice President
Daniel Karp, Executive Vice President - Corporate Development
Anirvan Ghosh, Senior Vice President - Research and Early Development
Michael CPA, Executive CFO
Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS)
Stelios Papadopoulos, Independent Chairman of the Board
Adam Keeney, Executive Development
Robert Pangia, Independent Director
Matt Griffiths, Senior Vice President CIO
Jeffrey Capello, CFO, Executive Vice President
Jesus Mantas, Director
Richard Mulligan, Independent Director
Michel Vounatsos, Vice President and Chief Commercial Officer
Sanjay Jariwala, Senior Vice President - Worldwide Medical
Susan Esq, Executive Officer
George Scangos, CEO and Director
Adriana Karaboutis, Executive VP of Technology, Bus. Solutions and Corporate Affairs
Mark Hernon, Senior Vice President CIO
Stephen Sherwin, Independent Director
Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation
Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary
Catherine Steele, Senior Vice President - Corporate Affairs
Paul Clancy, CFO and Executive VP of Fin.
Steven Holtzman, Executive Vice President - Corporate Development
Nancy Leaming, Independent Director
Nicole Murphy, Head Technology
Michael Hencke, Head Relations
Lynn Schenk, Independent Director
Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area
Brian Posner, Independent Director
Gregory Covino, Chief Accounting Officer, VP of Fin. and Controller
Alisha Alaimo, President America
John Cox, Executive VP of Pharmaceutical Operations and Technology

Biogen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Biogen Investors Sentiment

The influence of Biogen's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biogen. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biogen's public news can be used to forecast risks associated with an investment in Biogen. The trend in average sentiment can be used to explain how an investor holding Biogen can time the market purely based on public headlines and social activities around Biogen Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biogen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biogen's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biogen's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biogen.

Biogen Implied Volatility

    
  52.59  
Biogen's implied volatility exposes the market's sentiment of Biogen Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biogen's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biogen stock will not fluctuate a lot when Biogen's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biogen's short interest history, or implied volatility extrapolated from Biogen options trading.

Pair Trading with Biogen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biogen Stock

  0.8MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biogen Stock

  0.92EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.9DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.81MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.77TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.55)
Earnings Share
7.96
Revenue Per Share
67.972
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0458
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.